Johnson & Johnson has raised its full-year 2026 revenue guidance to US$101.2 billion after reporting third-quarter sales of US$25.4 billion, putting the healthcare company on track to surpass the US$100 billion milestone for the first time in its 140-year history.
Announced on 13 October 2026, the results reflect continued growth in its Innovative Medicine division, supported by demand for key immunology and oncology treatments. The company also reported growth in its MedTech business, although the division fell short of expectations.
Johnson & Johnson Raises Full-Year Guidance
Johnson & Johnson recorded third-quarter sales of US$25.4 billion, representing a 5.9% increase compared with the same period in 2025.
The company raised its full-year reported sales guidance to a midpoint of US$101.2 billion, up from its previous estimate of US$101.1 billion. It also increased its adjusted earnings-per-share guidance to US$11.10.
Chief Executive Officer Joaquin Duato attributed the performance to the company’s focused portfolio and continued investment in high-growth areas.
The revised outlook reflects the company’s confidence in its ability to sustain growth across its pharmaceutical and medical technology operations.
Innovative Medicine Drives Quarterly Growth
Johnson & Johnson’s Innovative Medicine division generated US$16.8 billion in third-quarter sales, increasing 7.7% year on year.
Growth was supported by several treatments across immunology, oncology and neuroscience. Immunology medicine Tremfya recorded a 68% increase in sales, while oncology products, including Darzalex and Tecvayli, also contributed to the division’s performance.
Caplyta, used as an adjunctive treatment for major depressive disorder, reached US$1 billion in year-to-date sales, adding to the company’s portfolio of established commercial products.
Johnson & Johnson now has 29 products and platforms generating at least US$1 billion in annual sales across its Innovative Medicine and MedTech divisions.
Oncology Remains a Strategic Growth Priority
Oncology continues to be a major focus of Johnson & Johnson’s growth strategy.
The company is targeting annual oncology revenue exceeding US$50 billion by 2030, with the ambition of becoming a leading company in the field.
Its oncology portfolio includes treatments such as Darzalex, Tecvayli and Rybrevant, which contribute to its presence across several cancer treatment areas.
Continued investment in oncology research, product development and commercialisation is expected to remain important to the company’s long-term expansion plans.
MedTech Records Growth but Falls Short of Expectations
Johnson & Johnson’s MedTech division generated US$8.6 billion in third-quarter sales, representing 2.5% growth year on year.
Performance was supported by electrophysiology and shockwave technologies in cardiovascular care, contact lenses in vision and trauma products in orthopaedics.
Despite the increase in sales, the division fell short of the company’s expectations for the quarter. Management maintained its confidence in the division’s longer-term direction while acknowledging the need to improve performance.
Diversified Portfolio Supports Revenue Ambitions
Johnson & Johnson’s latest results highlight the role of its diversified healthcare portfolio in supporting growth across pharmaceuticals and medical technology.
The company’s increased revenue guidance places it above the US$100 billion milestone, while its investments in oncology, immunology and MedTech innovation remain central to its long-term strategy.
As the company advances towards its 2030 growth ambitions, its ability to sustain demand for established medicines, develop new treatments and strengthen its medical technology portfolio will be important to maintaining momentum.
